

# Naveni<sup>®</sup> PD1/PD-L1 Atto647N

BRINGING PRECISION TO SPATIAL PROTEOMICS



## Illuminate PD1/PD-L1 Interactions: Revolutionizing Immune Checkpoint Activation Detection

Unlocking the potential of immune checkpoint inhibition therapy calls for precise patient stratification<sup>1</sup>. While PD-L1 is a commonly used biomarker, its correlation with immunotherapy outcomes isn't always linear<sup>2</sup>. Addressing this challenge, Navinci presents Naveni<sup>®</sup> PD1/PD-L1 Atto647N, the pioneering fluorescent assay for *in situ* detection of PD1/PD-L1 interactions.

## Naveni<sup>®</sup> PD1/PD-L1 Atto647N enables you to:

- Identify PD1/PD-L1 interactions with exceptional specificity
- Visualize PD1/PD-L1 in the tumor microenvironment
- Enhance understanding of signaling pathways in the context of immune checkpoint blockade
- Uncover the diagnostic potential of the PD1/PD-L1 interaction

The Naveni® PD1/PD-L1 Atto647N kit is based on our proprietary Naveni® Proximity Ligation Technology<sup>3</sup>. The kit includes two Navenibodies conjugated to proprietary oligo arms (depicted as orange antibodies in the illustration). Only if the Navenibodies are in close proximity will they generate a rolling circle amplification reaction, leading to a strong and distinct dot. The kit is compatible with IF co-staining.



Non-small-cell lung cancer samples positive and negative for the PD1/PD-L1 interaction (magenta). Tumor tissue visualized by cytokeratin co-staining (yellow).

## Ordering information

Product	Code	Read out	Primary antibodies required
Naveni PD1/PD-L1 Atto647N	PPI.PDL1.FR.100	Fluorescence	Primary included
Naveni PD1/PD-L1 HRP	PPI.PDL1.HRP.100	Brightfield	Primary included
Naveni PD1/PD-L1 AP	PPI.PDL1.AP.100	Brightfield and fluorescence	Primary included

Kit size: 4ml working solution.  
For research use only. Not for use in diagnostic procedures.

1. Robert, C. A decade of immune-checkpoint inhibitors in cancer therapy. *Nat Commun* 11, 3801 (2020).
2. Sánchez-Magraner L, et al., High PD-1/PD-L1 Checkpoint Interaction Infers Tumor Selection and Therapeutic Sensitivity to Anti-PD-1/PD-L1 Treatment. *Cancer Res* 80, 19 (2020).
3. Klaesson A, et al., Improved efficiency of in situ protein analysis by proximity ligation using UnFold probes. *Sci Rep.* 8(1):5400 (2018).



**Your Distributor:**  
**BIOMOL GmbH**  
 Kieler Straße 303a · 22525 Hamburg · Germany  
 info@biomol.de · www.biomol.de · www.biomol.com  
 Tel. 040-853 260 0 · TOLL FREE: Tel. 0800-246 66 51

For research use only.  
Not for use in diagnostic or therapeutic procedures.

